Rhythm Pharmaceuticals to Present at Upcoming Conference
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a biopharmaceutical company committed to enhancing the lives of patients with rare neuroendocrine diseases, has announced that Dr. David Meeker, the Chair, President, and Chief Executive Officer, will take part in a fireside chat at the Wells Fargo Healthcare Conference. This event is set to occur at Encore Boston Harbor, where Dr. Meeker will engage in a detailed discussion about their innovative treatments at 3:45 p.m. ET on September 5, 2024.
Live Webcast Available
For those interested, the fireside chat will be live-streamed and can be found in the "Events & Presentations" section of the company’s Investor Relations webpage. Additionally, a replay of the event will be available for 30 days, offering an opportunity for those unable to attend live to catch up on the valuable insights shared during the presentation.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is leading the way in biopharmaceutical innovation, particularly in the realm of rare neuroendocrine diseases. Their flagship product, IMCIVREE (setmelanotide), is crucial in treating hyperphagia and severe obesity. The FDA has approved setmelanotide for chronic weight management in patients aged six and older who have specific genetic forms of obesity. These genetic conditions include deficiencies in POMC, PCSK1, or LEPR, which can be confirmed through genetic testing.
Regulatory Approvals Across Regions
Beyond its approval in the United States, setmelanotide has also received authorization from both the European Commission (EC) and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) for treating obesity and managing hunger in certain patient populations. This includes individuals genetically confirmed to have Bardet-Biedl syndrome and related deficiencies. Notably, the EC permits this medication for children as young as 2, showcasing Rhythm's dedication to pediatric care.
Broad Clinical Development Programs
In addition to its approved therapy, Rhythm is broadening its clinical development efforts for setmelanotide to include other rare diseases. The company is also investigating MC4R agonists such as LB54640 and RM-718, along with developing a range of small molecules aimed at treating congenital hyperinsulinism. This diverse pipeline reflects Rhythm's ambitious strategy to tackle significant unmet medical needs.
Setmelanotide Indications and Limitations
In the U.S., setmelanotide is indicated for chronic weight management in both adult and pediatric patients with specific genetic conditions related to obesity. It is important to understand that setmelanotide is not recommended for individuals with non-genetic obesity or benign genetic variants. A proper diagnosis through an FDA-approved test is essential before starting treatment.
Considerations and Precautions
Potential patients should be informed about important safety information regarding setmelanotide. It is contraindicated for those who have a serious hypersensitivity to the medication. There are significant warnings associated with the drug, including risks of increased skin pigmentation, the need for monitoring heart rate and blood pressure, and potential psychological effects such as depression or suicidal thoughts. Continuous assessment is vital for individuals undergoing treatment, particularly in pediatric populations, to monitor growth and any side effects.
Adverse Reactions and Specific Populations
Reported adverse reactions linked to setmelanotide include skin hyperpigmentation, injection site reactions, nausea, and more. Individuals who are breastfeeding should consult their healthcare provider about the risks associated with using this medication during lactation.
Contact Information for Rhythm Pharmaceuticals
For any questions or to report suspected adverse reactions, Rhythm Pharmaceuticals encourages individuals to reach out directly. David Connolly, the Head of Investor Relations and Corporate Communications, is available at 857-264-4280 or via email.
Frequently Asked Questions
What is Rhythm Pharmaceuticals known for?
Rhythm Pharmaceuticals specializes in developing treatments for rare neuroendocrine diseases, utilizing innovative therapeutics like setmelanotide.
Who will be presenting at the Wells Fargo Healthcare Conference?
Dr. David Meeker, the Chair, President, and Chief Executive Officer of Rhythm Pharmaceuticals, will be presenting at the conference.
How can I access the conference webcast?
You can access the webcast of the fireside chat through the "Events & Presentations" section of Rhythm's Investor Relations website.
What approvals does setmelanotide have?
Setmelanotide has received FDA approval for chronic weight management in specific types of obesity, and it is also authorized by the European Commission and MHRA for certain genetic conditions associated with obesity.
What should patients be cautious of while taking setmelanotide?
Patients should be aware of potential adverse reactions and the necessity for ongoing medical supervision during treatment, particularly concerning psychological effects and physical health monitoring.
